Long-Term Visual Outcomes for a Treat-and-Extend Antivascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration: Up to Seven-Year Follow-Up

Table 4

Evolution of BCVA and CRT across selected timepoints.

Timepoint		Visual acuity					Anatomical outcomes
Year	Month	n	BCVA, mean (LogMAR) ± SD	BCVA change from baseline, mean (LogMAR) ± SD	value	n		CRT, mean (μm) ± SD	CRT change from baseline, mean (μm) ± SD	value
	0	180	0.77 ± 0.64	—	—	56		402 ± 194	—	—
	3	180	0.69 ± 0.58	−0.08 ± 0.39	0.0057	49		313 ± 140	−86 ± 152	0.0002
	6	180	0.64 ± 0.55	−0.13 ± 0.43	0.0001	45		286 ± 102	−116 ± 164	0.0001
1	12	180	0.69 ± 0.60	−0.07 ± 0.51	0.0585	48		313 ± 143	−91 ± 175	0.0007
	18	173	0.65 ± 0.54	−0.13 ± 0.48	0.0007	49		302 ± 136	−89 ± 168	0.0005
2	24	172	0.68 ± 0.65	−0.08 ± 0.53	0.0485	51		306 ± 155	−107 ± 210	0.0006
	30	171	0.67 ± 0.60	−0.10 ± 0.51	0.0105	42		304 ± 175	−105 ± 204	0.0018
3	36	155	0.71 ± 0.62	−0.07 ± 0.54	0.1360	35		354 ± 237	−52 ± 203	0.1345
	42	135	0.67 ± 0.53	−0.08 ± 0.55	0.0831	33		324 ± 182	−64 ± 198	0.0743
4	48	92	0.69 ± 0.52	−0.04 ± 0.56	0.4534	4		283 ± 85	−106 ± 255	—
	54	82	0.74 ± 0.63	0.01 ± 0.59	0.8189	—		—	—	—
5	60	55	0.76 ± 0.56	0.02 ± 0.57	0.7782	—		—	—	—
	66	50	0.74 ± 0.59	0.03 ± 0.67	0.7383	—		—	—	—
6	72	32	0.76 ± 0.71	0.09 ± 0.47	0.3081	—		—	—	—
	78	26	0.72 ± 0.74	0.02 ± 0.50	0.7795	—		—	—	—
7	84	9	0.91 ± 0.91	0.08 ± 0.49	—	—		—	—	—

value for BCVA/CRT change at different timepoints in comparison to baseline BCVA/CRT. Sample size too small to conduct statistical analysis.